nodes	percent_of_prediction	percent_of_DWPC	metapath
Loxapine—Gynaecomastia—Sorafenib—liver cancer	0.00842	0.0261	CcSEcCtD
Loxapine—Dysphagia—Sorafenib—liver cancer	0.00591	0.0183	CcSEcCtD
Loxapine—Weight decreased—Sorafenib—liver cancer	0.00534	0.0166	CcSEcCtD
Loxapine—Renal failure—Sorafenib—liver cancer	0.00518	0.0161	CcSEcCtD
Loxapine—Jaundice—Sorafenib—liver cancer	0.00513	0.0159	CcSEcCtD
Loxapine—Seborrhoeic dermatitis—Epirubicin—liver cancer	0.0051	0.0158	CcSEcCtD
Loxapine—Seborrhoeic dermatitis—Doxorubicin—liver cancer	0.00472	0.0147	CcSEcCtD
Loxapine—Angiopathy—Sorafenib—liver cancer	0.00429	0.0133	CcSEcCtD
Loxapine—Mediastinal disorder—Sorafenib—liver cancer	0.00426	0.0132	CcSEcCtD
Loxapine—Alopecia—Sorafenib—liver cancer	0.00418	0.013	CcSEcCtD
Loxapine—Liver injury—Epirubicin—liver cancer	0.00413	0.0128	CcSEcCtD
Loxapine—Dysgeusia—Sorafenib—liver cancer	0.00403	0.0125	CcSEcCtD
Loxapine—Amenorrhoea—Epirubicin—liver cancer	0.00396	0.0123	CcSEcCtD
Loxapine—Muscle spasms—Sorafenib—liver cancer	0.00396	0.0123	CcSEcCtD
Loxapine—Liver injury—Doxorubicin—liver cancer	0.00383	0.0119	CcSEcCtD
Loxapine—Dyskinesia—Epirubicin—liver cancer	0.0037	0.0115	CcSEcCtD
Loxapine—Syncope—Sorafenib—liver cancer	0.00369	0.0115	CcSEcCtD
Loxapine—Leukopenia—Sorafenib—liver cancer	0.00368	0.0114	CcSEcCtD
Loxapine—Dysarthria—Epirubicin—liver cancer	0.00368	0.0114	CcSEcCtD
Loxapine—Amenorrhoea—Doxorubicin—liver cancer	0.00366	0.0114	CcSEcCtD
Loxapine—Loss of consciousness—Sorafenib—liver cancer	0.00362	0.0112	CcSEcCtD
Loxapine—Cough—Sorafenib—liver cancer	0.00359	0.0111	CcSEcCtD
Loxapine—Gait disturbance—Epirubicin—liver cancer	0.00356	0.0111	CcSEcCtD
Loxapine—Hypertension—Sorafenib—liver cancer	0.00355	0.011	CcSEcCtD
Loxapine—Hepatocellular injury—Epirubicin—liver cancer	0.00348	0.0108	CcSEcCtD
Loxapine—Dry mouth—Sorafenib—liver cancer	0.00343	0.0106	CcSEcCtD
Loxapine—Dyskinesia—Doxorubicin—liver cancer	0.00342	0.0106	CcSEcCtD
Loxapine—Dysarthria—Doxorubicin—liver cancer	0.0034	0.0106	CcSEcCtD
Loxapine—Salivary hypersecretion—Epirubicin—liver cancer	0.00338	0.0105	CcSEcCtD
Loxapine—Shock—Sorafenib—liver cancer	0.0033	0.0103	CcSEcCtD
Loxapine—Gait disturbance—Doxorubicin—liver cancer	0.0033	0.0102	CcSEcCtD
Loxapine—Nervous system disorder—Sorafenib—liver cancer	0.00329	0.0102	CcSEcCtD
Loxapine—Thrombocytopenia—Sorafenib—liver cancer	0.00329	0.0102	CcSEcCtD
Loxapine—Hepatocellular injury—Doxorubicin—liver cancer	0.00322	0.00999	CcSEcCtD
Loxapine—Dry eye—Epirubicin—liver cancer	0.00321	0.00997	CcSEcCtD
Loxapine—Salivary hypersecretion—Doxorubicin—liver cancer	0.00313	0.0097	CcSEcCtD
Loxapine—Dyspnoea—Sorafenib—liver cancer	0.00299	0.00929	CcSEcCtD
Loxapine—Dry eye—Doxorubicin—liver cancer	0.00297	0.00923	CcSEcCtD
Loxapine—Gastrointestinal disorder—Sorafenib—liver cancer	0.0029	0.009	CcSEcCtD
Loxapine—Fatigue—Sorafenib—liver cancer	0.0029	0.00899	CcSEcCtD
Loxapine—Photosensitivity—Epirubicin—liver cancer	0.00288	0.00893	CcSEcCtD
Loxapine—Constipation—Sorafenib—liver cancer	0.00287	0.00891	CcSEcCtD
Loxapine—Photosensitivity—Doxorubicin—liver cancer	0.00266	0.00826	CcSEcCtD
Loxapine—Cerebrovascular accident—Epirubicin—liver cancer	0.00258	0.008	CcSEcCtD
Loxapine—Hypersensitivity—Sorafenib—liver cancer	0.00247	0.00768	CcSEcCtD
Loxapine—Asthenia—Sorafenib—liver cancer	0.00241	0.00748	CcSEcCtD
Loxapine—Azelastine—CYP2E1—liver cancer	0.0024	0.223	CrCbGaD
Loxapine—Cerebrovascular accident—Doxorubicin—liver cancer	0.00238	0.0074	CcSEcCtD
Loxapine—Pruritus—Sorafenib—liver cancer	0.00238	0.00737	CcSEcCtD
Loxapine—Azelastine—CYP1A1—liver cancer	0.00237	0.22	CrCbGaD
Loxapine—Orthostatic hypotension—Epirubicin—liver cancer	0.00231	0.00716	CcSEcCtD
Loxapine—Dizziness—Sorafenib—liver cancer	0.00222	0.00689	CcSEcCtD
Loxapine—Dysphagia—Epirubicin—liver cancer	0.00218	0.00677	CcSEcCtD
Loxapine—Vomiting—Sorafenib—liver cancer	0.00214	0.00663	CcSEcCtD
Loxapine—Orthostatic hypotension—Doxorubicin—liver cancer	0.00213	0.00662	CcSEcCtD
Loxapine—Rash—Sorafenib—liver cancer	0.00212	0.00657	CcSEcCtD
Loxapine—Dermatitis—Sorafenib—liver cancer	0.00212	0.00657	CcSEcCtD
Loxapine—Headache—Sorafenib—liver cancer	0.0021	0.00653	CcSEcCtD
Loxapine—Dysphagia—Doxorubicin—liver cancer	0.00202	0.00627	CcSEcCtD
Loxapine—Nausea—Sorafenib—liver cancer	0.00199	0.00619	CcSEcCtD
Loxapine—Photosensitivity reaction—Epirubicin—liver cancer	0.00199	0.00618	CcSEcCtD
Loxapine—Weight increased—Epirubicin—liver cancer	0.00199	0.00616	CcSEcCtD
Loxapine—Weight decreased—Epirubicin—liver cancer	0.00197	0.00613	CcSEcCtD
Loxapine—Drowsiness—Epirubicin—liver cancer	0.00195	0.00604	CcSEcCtD
Loxapine—Renal failure—Epirubicin—liver cancer	0.00191	0.00594	CcSEcCtD
Loxapine—Jaundice—Epirubicin—liver cancer	0.0019	0.00589	CcSEcCtD
Loxapine—Photosensitivity reaction—Doxorubicin—liver cancer	0.00184	0.00572	CcSEcCtD
Loxapine—Weight increased—Doxorubicin—liver cancer	0.00184	0.0057	CcSEcCtD
Loxapine—Weight decreased—Doxorubicin—liver cancer	0.00183	0.00567	CcSEcCtD
Loxapine—Agranulocytosis—Epirubicin—liver cancer	0.00182	0.00564	CcSEcCtD
Loxapine—Drowsiness—Doxorubicin—liver cancer	0.0018	0.00559	CcSEcCtD
Loxapine—Renal failure—Doxorubicin—liver cancer	0.00177	0.00549	CcSEcCtD
Loxapine—Jaundice—Doxorubicin—liver cancer	0.00176	0.00545	CcSEcCtD
Loxapine—Hepatitis—Epirubicin—liver cancer	0.00175	0.00542	CcSEcCtD
Loxapine—Hypoaesthesia—Epirubicin—liver cancer	0.00174	0.00539	CcSEcCtD
Loxapine—Agranulocytosis—Doxorubicin—liver cancer	0.00168	0.00522	CcSEcCtD
Loxapine—Hepatitis—Doxorubicin—liver cancer	0.00162	0.00502	CcSEcCtD
Loxapine—Hypoaesthesia—Doxorubicin—liver cancer	0.00161	0.00499	CcSEcCtD
Loxapine—Angiopathy—Epirubicin—liver cancer	0.00158	0.00492	CcSEcCtD
Loxapine—Mediastinal disorder—Epirubicin—liver cancer	0.00157	0.00489	CcSEcCtD
Loxapine—Alopecia—Epirubicin—liver cancer	0.00154	0.00479	CcSEcCtD
Loxapine—Tension—Epirubicin—liver cancer	0.00149	0.00463	CcSEcCtD
Loxapine—Dysgeusia—Epirubicin—liver cancer	0.00149	0.00462	CcSEcCtD
Loxapine—Angiopathy—Doxorubicin—liver cancer	0.00147	0.00455	CcSEcCtD
Loxapine—Muscle spasms—Epirubicin—liver cancer	0.00146	0.00454	CcSEcCtD
Loxapine—Mediastinal disorder—Doxorubicin—liver cancer	0.00146	0.00452	CcSEcCtD
Loxapine—Vision blurred—Epirubicin—liver cancer	0.00143	0.00445	CcSEcCtD
Loxapine—Alopecia—Doxorubicin—liver cancer	0.00143	0.00443	CcSEcCtD
Loxapine—Agitation—Epirubicin—liver cancer	0.0014	0.00434	CcSEcCtD
Loxapine—Tension—Doxorubicin—liver cancer	0.00138	0.00429	CcSEcCtD
Loxapine—Dysgeusia—Doxorubicin—liver cancer	0.00138	0.00428	CcSEcCtD
Loxapine—Syncope—Epirubicin—liver cancer	0.00136	0.00423	CcSEcCtD
Loxapine—Leukopenia—Epirubicin—liver cancer	0.00136	0.00422	CcSEcCtD
Loxapine—Muscle spasms—Doxorubicin—liver cancer	0.00135	0.0042	CcSEcCtD
Loxapine—Loss of consciousness—Epirubicin—liver cancer	0.00134	0.00415	CcSEcCtD
Loxapine—Cough—Epirubicin—liver cancer	0.00133	0.00412	CcSEcCtD
Loxapine—Vision blurred—Doxorubicin—liver cancer	0.00133	0.00412	CcSEcCtD
Loxapine—Convulsion—Epirubicin—liver cancer	0.00132	0.00409	CcSEcCtD
Loxapine—Hypertension—Epirubicin—liver cancer	0.00131	0.00407	CcSEcCtD
Loxapine—Chest pain—Epirubicin—liver cancer	0.00129	0.00402	CcSEcCtD
Loxapine—Agitation—Doxorubicin—liver cancer	0.00129	0.00401	CcSEcCtD
Loxapine—Dry mouth—Epirubicin—liver cancer	0.00127	0.00393	CcSEcCtD
Loxapine—Syncope—Doxorubicin—liver cancer	0.00126	0.00392	CcSEcCtD
Loxapine—Leukopenia—Doxorubicin—liver cancer	0.00126	0.00391	CcSEcCtD
Loxapine—Confusional state—Epirubicin—liver cancer	0.00125	0.00388	CcSEcCtD
Loxapine—Oedema—Epirubicin—liver cancer	0.00124	0.00385	CcSEcCtD
Loxapine—Loss of consciousness—Doxorubicin—liver cancer	0.00124	0.00384	CcSEcCtD
Loxapine—Cough—Doxorubicin—liver cancer	0.00123	0.00381	CcSEcCtD
Loxapine—Shock—Epirubicin—liver cancer	0.00122	0.00379	CcSEcCtD
Loxapine—Convulsion—Doxorubicin—liver cancer	0.00122	0.00378	CcSEcCtD
Loxapine—Nervous system disorder—Epirubicin—liver cancer	0.00122	0.00378	CcSEcCtD
Loxapine—Thrombocytopenia—Epirubicin—liver cancer	0.00122	0.00377	CcSEcCtD
Loxapine—Hypertension—Doxorubicin—liver cancer	0.00121	0.00377	CcSEcCtD
Loxapine—Tachycardia—Epirubicin—liver cancer	0.00121	0.00376	CcSEcCtD
Loxapine—Chest pain—Doxorubicin—liver cancer	0.0012	0.00372	CcSEcCtD
Loxapine—Dry mouth—Doxorubicin—liver cancer	0.00117	0.00364	CcSEcCtD
Loxapine—Hypotension—Epirubicin—liver cancer	0.00116	0.0036	CcSEcCtD
Loxapine—Confusional state—Doxorubicin—liver cancer	0.00116	0.00359	CcSEcCtD
Loxapine—Oedema—Doxorubicin—liver cancer	0.00115	0.00356	CcSEcCtD
Loxapine—Olanzapine—ALB—liver cancer	0.00113	0.105	CrCbGaD
Loxapine—Shock—Doxorubicin—liver cancer	0.00113	0.00351	CcSEcCtD
Loxapine—Nervous system disorder—Doxorubicin—liver cancer	0.00113	0.0035	CcSEcCtD
Loxapine—Thrombocytopenia—Doxorubicin—liver cancer	0.00112	0.00349	CcSEcCtD
Loxapine—Insomnia—Epirubicin—liver cancer	0.00112	0.00348	CcSEcCtD
Loxapine—Tachycardia—Doxorubicin—liver cancer	0.00112	0.00348	CcSEcCtD
Loxapine—Paraesthesia—Epirubicin—liver cancer	0.00111	0.00346	CcSEcCtD
Loxapine—Dyspnoea—Epirubicin—liver cancer	0.00111	0.00343	CcSEcCtD
Loxapine—Somnolence—Epirubicin—liver cancer	0.0011	0.00342	CcSEcCtD
Loxapine—Diazepam—CYP2E1—liver cancer	0.00109	0.101	CrCbGaD
Loxapine—Clozapine—CYP2E1—liver cancer	0.00108	0.1	CrCbGaD
Loxapine—Hypotension—Doxorubicin—liver cancer	0.00107	0.00333	CcSEcCtD
Loxapine—Gastrointestinal disorder—Epirubicin—liver cancer	0.00107	0.00333	CcSEcCtD
Loxapine—Fatigue—Epirubicin—liver cancer	0.00107	0.00332	CcSEcCtD
Loxapine—Clozapine—CYP1A1—liver cancer	0.00106	0.0987	CrCbGaD
Loxapine—Constipation—Epirubicin—liver cancer	0.00106	0.00329	CcSEcCtD
Loxapine—Insomnia—Doxorubicin—liver cancer	0.00104	0.00322	CcSEcCtD
Loxapine—Paraesthesia—Doxorubicin—liver cancer	0.00103	0.0032	CcSEcCtD
Loxapine—Thiothixene—ALB—liver cancer	0.00103	0.0954	CrCbGaD
Loxapine—Dyspnoea—Doxorubicin—liver cancer	0.00102	0.00318	CcSEcCtD
Loxapine—Feeling abnormal—Epirubicin—liver cancer	0.00102	0.00317	CcSEcCtD
Loxapine—Somnolence—Doxorubicin—liver cancer	0.00102	0.00317	CcSEcCtD
Loxapine—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000991	0.00308	CcSEcCtD
Loxapine—Fatigue—Doxorubicin—liver cancer	0.00099	0.00307	CcSEcCtD
Loxapine—Constipation—Doxorubicin—liver cancer	0.000982	0.00305	CcSEcCtD
Loxapine—Feeling abnormal—Doxorubicin—liver cancer	0.000946	0.00294	CcSEcCtD
Loxapine—Hypersensitivity—Epirubicin—liver cancer	0.000914	0.00284	CcSEcCtD
Loxapine—Asthenia—Epirubicin—liver cancer	0.00089	0.00276	CcSEcCtD
Loxapine—Pruritus—Epirubicin—liver cancer	0.000878	0.00273	CcSEcCtD
Loxapine—Hypersensitivity—Doxorubicin—liver cancer	0.000846	0.00263	CcSEcCtD
Loxapine—Asthenia—Doxorubicin—liver cancer	0.000824	0.00256	CcSEcCtD
Loxapine—Dizziness—Epirubicin—liver cancer	0.000821	0.00255	CcSEcCtD
Loxapine—Pruritus—Doxorubicin—liver cancer	0.000812	0.00252	CcSEcCtD
Loxapine—Vomiting—Epirubicin—liver cancer	0.000789	0.00245	CcSEcCtD
Loxapine—Rash—Epirubicin—liver cancer	0.000783	0.00243	CcSEcCtD
Loxapine—Dermatitis—Epirubicin—liver cancer	0.000782	0.00243	CcSEcCtD
Loxapine—Headache—Epirubicin—liver cancer	0.000777	0.00241	CcSEcCtD
Loxapine—Dizziness—Doxorubicin—liver cancer	0.000759	0.00236	CcSEcCtD
Loxapine—Nausea—Epirubicin—liver cancer	0.000737	0.00229	CcSEcCtD
Loxapine—Vomiting—Doxorubicin—liver cancer	0.00073	0.00227	CcSEcCtD
Loxapine—Rash—Doxorubicin—liver cancer	0.000724	0.00225	CcSEcCtD
Loxapine—Dermatitis—Doxorubicin—liver cancer	0.000723	0.00225	CcSEcCtD
Loxapine—Headache—Doxorubicin—liver cancer	0.000719	0.00223	CcSEcCtD
Loxapine—Nausea—Doxorubicin—liver cancer	0.000682	0.00212	CcSEcCtD
Loxapine—Diazepam—ALB—liver cancer	0.000599	0.0557	CrCbGaD
Loxapine—CHRM1—Signaling by GPCR—IL6—liver cancer	3.31e-05	4.97e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—JUN—liver cancer	3.31e-05	4.96e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling by GPCR—IL6—liver cancer	3.3e-05	4.95e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—VEGFA—liver cancer	3.29e-05	4.94e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—CASP3—liver cancer	3.29e-05	4.94e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—IL2—liver cancer	3.29e-05	4.93e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—CTNNB1—liver cancer	3.28e-05	4.92e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—CASP3—liver cancer	3.28e-05	4.92e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—IL2—liver cancer	3.28e-05	4.91e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—PIK3CA—liver cancer	3.28e-05	4.91e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—VEGFA—liver cancer	3.28e-05	4.91e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling by GPCR—IL6—liver cancer	3.27e-05	4.9e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—TP53—liver cancer	3.27e-05	4.9e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—CCND1—liver cancer	3.26e-05	4.89e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling by GPCR—IL6—liver cancer	3.26e-05	4.89e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—STAT3—liver cancer	3.26e-05	4.89e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—JUN—liver cancer	3.26e-05	4.88e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—CCND1—liver cancer	3.26e-05	4.88e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—KRAS—liver cancer	3.26e-05	4.88e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—JUN—liver cancer	3.25e-05	4.87e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—CCND1—liver cancer	3.25e-05	4.87e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—STAT3—liver cancer	3.24e-05	4.86e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—JUN—liver cancer	3.24e-05	4.86e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—CCND1—liver cancer	3.24e-05	4.85e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—CTNNB1—liver cancer	3.23e-05	4.85e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—JUN—liver cancer	3.23e-05	4.84e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—CTNNB1—liver cancer	3.23e-05	4.83e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—MMP9—liver cancer	3.22e-05	4.83e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—HRAS—liver cancer	3.22e-05	4.82e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—CTNNB1—liver cancer	3.21e-05	4.82e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—TP53—liver cancer	3.21e-05	4.82e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—KRAS—liver cancer	3.21e-05	4.82e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—HRAS—liver cancer	3.21e-05	4.81e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—CDKN1A—liver cancer	3.21e-05	4.81e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—CCND1—liver cancer	3.2e-05	4.8e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—CTNNB1—liver cancer	3.2e-05	4.8e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—JUN—liver cancer	3.2e-05	4.79e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—CCND1—liver cancer	3.2e-05	4.79e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—HRAS—liver cancer	3.19e-05	4.78e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—JUN—liver cancer	3.19e-05	4.78e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—VEGFA—liver cancer	3.19e-05	4.78e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—CTNNB1—liver cancer	3.17e-05	4.76e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—TP53—liver cancer	3.17e-05	4.75e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—MMP9—liver cancer	3.17e-05	4.75e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—MYC—liver cancer	3.17e-05	4.75e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—HRAS—liver cancer	3.17e-05	4.75e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—CTNNB1—liver cancer	3.16e-05	4.74e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—MMP9—liver cancer	3.16e-05	4.74e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—TGFB1—liver cancer	3.16e-05	4.74e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—CDKN1A—liver cancer	3.16e-05	4.73e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—STAT3—liver cancer	3.16e-05	4.73e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—MMP9—liver cancer	3.15e-05	4.72e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—CDKN1A—liver cancer	3.15e-05	4.72e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—MMP9—liver cancer	3.14e-05	4.71e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—CDKN1A—liver cancer	3.14e-05	4.71e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—PIK3CA—liver cancer	3.14e-05	4.71e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—MYC—liver cancer	3.14e-05	4.71e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—VEGFA—liver cancer	3.14e-05	4.7e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—MAPK8—liver cancer	3.13e-05	4.7e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—TGFB1—liver cancer	3.13e-05	4.69e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—CDKN1A—liver cancer	3.13e-05	4.69e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—HRAS—liver cancer	3.12e-05	4.68e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling by GPCR—AKT1—liver cancer	3.12e-05	4.68e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CDKN1B—liver cancer	3.11e-05	4.67e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—MMP9—liver cancer	3.11e-05	4.66e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—STAT3—liver cancer	3.11e-05	4.66e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—MMP9—liver cancer	3.1e-05	4.65e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—CDKN1A—liver cancer	3.1e-05	4.65e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—CDKN1A—liver cancer	3.09e-05	4.63e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—MAPK8—liver cancer	3.08e-05	4.62e-05	CbGpPWpGaD
Loxapine—ADRA2A—GPCR downstream signaling—AKT1—liver cancer	3.08e-05	4.62e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—IL6—liver cancer	3.08e-05	4.61e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—MAPK8—liver cancer	3.08e-05	4.61e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—HRAS—liver cancer	3.07e-05	4.61e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—IL6—liver cancer	3.07e-05	4.61e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling by GPCR—AKT1—liver cancer	3.07e-05	4.61e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling by GPCR—AKT1—liver cancer	3.07e-05	4.6e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—MAPK8—liver cancer	3.07e-05	4.6e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling by GPCR—AKT1—liver cancer	3.06e-05	4.58e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—MAPK8—liver cancer	3.06e-05	4.58e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—IL6—liver cancer	3.05e-05	4.58e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CASP3—liver cancer	3.05e-05	4.57e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling by GPCR—AKT1—liver cancer	3.05e-05	4.57e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—IL2—liver cancer	3.05e-05	4.57e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—TP53—liver cancer	3.04e-05	4.55e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—HRAS—liver cancer	3.03e-05	4.55e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—IL6—liver cancer	3.03e-05	4.54e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—MYC—liver cancer	3.03e-05	4.54e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—MAPK8—liver cancer	3.03e-05	4.54e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—TGFB1—liver cancer	3.02e-05	4.53e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling by GPCR—AKT1—liver cancer	3.02e-05	4.52e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—MAPK8—liver cancer	3.02e-05	4.52e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—MYC—liver cancer	3.01e-05	4.52e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling by GPCR—AKT1—liver cancer	3.01e-05	4.51e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—TGFB1—liver cancer	3.01e-05	4.51e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—PIK3CA—liver cancer	2.99e-05	4.48e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—IL6—liver cancer	2.99e-05	4.48e-05	CbGpPWpGaD
Loxapine—ADRA2C—Metabolism—PIK3CA—liver cancer	2.98e-05	4.46e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CCND1—liver cancer	2.97e-05	4.45e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—JUN—liver cancer	2.96e-05	4.44e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—PIK3CA—liver cancer	2.95e-05	4.43e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—IL6—liver cancer	2.94e-05	4.41e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CTNNB1—liver cancer	2.94e-05	4.41e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—MYC—liver cancer	2.93e-05	4.4e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—KRAS—liver cancer	2.93e-05	4.39e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—TGFB1—liver cancer	2.93e-05	4.39e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—HRAS—liver cancer	2.9e-05	4.35e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—IL6—liver cancer	2.9e-05	4.35e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—KRAS—liver cancer	2.9e-05	4.35e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—TP53—liver cancer	2.89e-05	4.34e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—VEGFA—liver cancer	2.89e-05	4.34e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—MYC—liver cancer	2.89e-05	4.33e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—MMP9—liver cancer	2.88e-05	4.32e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—TGFB1—liver cancer	2.88e-05	4.32e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CDKN1A—liver cancer	2.87e-05	4.31e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—STAT3—liver cancer	2.86e-05	4.29e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—TP53—liver cancer	2.86e-05	4.28e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—VEGFA—liver cancer	2.85e-05	4.27e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—VEGFA—liver cancer	2.84e-05	4.26e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—AKT1—liver cancer	2.84e-05	4.26e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—AKT1—liver cancer	2.84e-05	4.25e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—VEGFA—liver cancer	2.83e-05	4.24e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—VEGFA—liver cancer	2.82e-05	4.23e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—AKT1—liver cancer	2.82e-05	4.22e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—STAT3—liver cancer	2.82e-05	4.22e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—STAT3—liver cancer	2.81e-05	4.21e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—MAPK8—liver cancer	2.8e-05	4.2e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—STAT3—liver cancer	2.8e-05	4.2e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—KRAS—liver cancer	2.8e-05	4.2e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—AKT1—liver cancer	2.8e-05	4.19e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—VEGFA—liver cancer	2.79e-05	4.19e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—STAT3—liver cancer	2.79e-05	4.19e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—VEGFA—liver cancer	2.79e-05	4.18e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—KRAS—liver cancer	2.79e-05	4.18e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—IL6—liver cancer	2.78e-05	4.17e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—HRAS—liver cancer	2.77e-05	4.15e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—STAT3—liver cancer	2.77e-05	4.15e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—AKT1—liver cancer	2.76e-05	4.14e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—STAT3—liver cancer	2.76e-05	4.14e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—HRAS—liver cancer	2.73e-05	4.09e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—AKT1—liver cancer	2.71e-05	4.07e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—KRAS—liver cancer	2.71e-05	4.06e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—PIK3CA—liver cancer	2.69e-05	4.03e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—AKT1—liver cancer	2.68e-05	4.01e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—KRAS—liver cancer	2.67e-05	4e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—PIK3CA—liver cancer	2.66e-05	4e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—MYC—liver cancer	2.66e-05	3.99e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—TGFB1—liver cancer	2.65e-05	3.98e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—IL6—liver cancer	2.65e-05	3.97e-05	CbGpPWpGaD
Loxapine—CHRM3—Metabolism—PIK3CA—liver cancer	2.64e-05	3.95e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—MYC—liver cancer	2.62e-05	3.92e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—IL6—liver cancer	2.61e-05	3.92e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—MYC—liver cancer	2.61e-05	3.92e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—TGFB1—liver cancer	2.61e-05	3.92e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—TGFB1—liver cancer	2.61e-05	3.91e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—MYC—liver cancer	2.6e-05	3.9e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—TP53—liver cancer	2.6e-05	3.9e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—TGFB1—liver cancer	2.6e-05	3.89e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—MYC—liver cancer	2.6e-05	3.89e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—TGFB1—liver cancer	2.59e-05	3.88e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—VEGFA—liver cancer	2.59e-05	3.88e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—TP53—liver cancer	2.58e-05	3.86e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—PIK3CA—liver cancer	2.57e-05	3.86e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—MYC—liver cancer	2.57e-05	3.85e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—AKT1—liver cancer	2.56e-05	3.84e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—TGFB1—liver cancer	2.56e-05	3.84e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—MYC—liver cancer	2.56e-05	3.84e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—STAT3—liver cancer	2.56e-05	3.84e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—PIK3CA—liver cancer	2.56e-05	3.84e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—TGFB1—liver cancer	2.56e-05	3.83e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—PIK3CA—liver cancer	2.49e-05	3.73e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—TP53—liver cancer	2.49e-05	3.73e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—HRAS—liver cancer	2.49e-05	3.73e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—TP53—liver cancer	2.48e-05	3.71e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—HRAS—liver cancer	2.47e-05	3.7e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—KRAS—liver cancer	2.46e-05	3.69e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—PIK3CA—liver cancer	2.45e-05	3.67e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—AKT1—liver cancer	2.44e-05	3.66e-05	CbGpPWpGaD
Loxapine—ADRA2C—Metabolism—AKT1—liver cancer	2.43e-05	3.65e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—KRAS—liver cancer	2.42e-05	3.63e-05	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—PIK3CA—liver cancer	2.42e-05	3.62e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—KRAS—liver cancer	2.41e-05	3.62e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—AKT1—liver cancer	2.41e-05	3.61e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—TP53—liver cancer	2.41e-05	3.61e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—KRAS—liver cancer	2.41e-05	3.61e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—KRAS—liver cancer	2.4e-05	3.6e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—MYC—liver cancer	2.38e-05	3.57e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—IL6—liver cancer	2.38e-05	3.57e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—HRAS—liver cancer	2.38e-05	3.57e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—TGFB1—liver cancer	2.38e-05	3.56e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—KRAS—liver cancer	2.38e-05	3.56e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—TP53—liver cancer	2.37e-05	3.55e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—KRAS—liver cancer	2.37e-05	3.55e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—HRAS—liver cancer	2.37e-05	3.55e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—IL6—liver cancer	2.36e-05	3.54e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—HRAS—liver cancer	2.3e-05	3.45e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—IL6—liver cancer	2.28e-05	3.41e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—HRAS—liver cancer	2.27e-05	3.4e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—IL6—liver cancer	2.27e-05	3.4e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—PIK3CA—liver cancer	2.26e-05	3.39e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—PIK3CA—liver cancer	2.22e-05	3.33e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—PIK3CA—liver cancer	2.22e-05	3.32e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—PIK3CA—liver cancer	2.21e-05	3.31e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—IL6—liver cancer	2.2e-05	3.3e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—PIK3CA—liver cancer	2.2e-05	3.3e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—KRAS—liver cancer	2.2e-05	3.3e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—AKT1—liver cancer	2.2e-05	3.29e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—TP53—liver cancer	2.19e-05	3.28e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—PIK3CA—liver cancer	2.18e-05	3.27e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—AKT1—liver cancer	2.18e-05	3.26e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—PIK3CA—liver cancer	2.18e-05	3.26e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—IL6—liver cancer	2.17e-05	3.25e-05	CbGpPWpGaD
Loxapine—CHRM3—Metabolism—AKT1—liver cancer	2.15e-05	3.23e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—TP53—liver cancer	2.15e-05	3.22e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—TP53—liver cancer	2.15e-05	3.22e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—TP53—liver cancer	2.14e-05	3.21e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—TP53—liver cancer	2.13e-05	3.2e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—TP53—liver cancer	2.11e-05	3.16e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—TP53—liver cancer	2.11e-05	3.16e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—AKT1—liver cancer	2.1e-05	3.15e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—AKT1—liver cancer	2.09e-05	3.13e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—HRAS—liver cancer	2.09e-05	3.13e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—HRAS—liver cancer	2.06e-05	3.08e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—HRAS—liver cancer	2.05e-05	3.08e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—HRAS—liver cancer	2.05e-05	3.07e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—HRAS—liver cancer	2.04e-05	3.06e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—AKT1—liver cancer	2.03e-05	3.05e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—PIK3CA—liver cancer	2.02e-05	3.03e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—HRAS—liver cancer	2.02e-05	3.03e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—HRAS—liver cancer	2.01e-05	3.02e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—AKT1—liver cancer	2e-05	3e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—IL6—liver cancer	2e-05	3e-05	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—AKT1—liver cancer	1.98e-05	2.96e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—IL6—liver cancer	1.97e-05	2.95e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—IL6—liver cancer	1.96e-05	2.94e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—IL6—liver cancer	1.96e-05	2.93e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—TP53—liver cancer	1.96e-05	2.93e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—IL6—liver cancer	1.95e-05	2.93e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—IL6—liver cancer	1.93e-05	2.9e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—IL6—liver cancer	1.93e-05	2.89e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—HRAS—liver cancer	1.87e-05	2.8e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—AKT1—liver cancer	1.85e-05	2.77e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—AKT1—liver cancer	1.82e-05	2.72e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—AKT1—liver cancer	1.81e-05	2.72e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—AKT1—liver cancer	1.81e-05	2.71e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—AKT1—liver cancer	1.8e-05	2.7e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—IL6—liver cancer	1.79e-05	2.68e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—AKT1—liver cancer	1.78e-05	2.67e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—AKT1—liver cancer	1.78e-05	2.66e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—AKT1—liver cancer	1.65e-05	2.48e-05	CbGpPWpGaD
